Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients

Inflammatory Bowel Diseases

Volumn 17, Issue 3, 2011, Pages 809-815

  Thia, Kelvin T ^a   Li, Meiqin ^a   Ling, Khoon Lin ^a   Kong, San Choon ^a   Ooi, Choon Jin ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Asian; azathioprine; corticosteroids; predictors; remission

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; MESALAZINE; SALAZOSULFAPYRIDINE;

ADULT; AGE; AGED; ARTICLE; ASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; ENTERITIS; ETHNICITY; FEMALE; HERPES SIMPLEX; HUMAN; LETHARGY; LEUKOCYTE COUNT; LEUKOPENIA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; PANCYTOPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; AZATHIOPRINE; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951626444     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21382     Document Type: Article

References (34)

1. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121: 255-260. (Pubitemid 32729372)
2. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994; 35: 360-362.
3. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130: 940-987. (Pubitemid 43374543)
4. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55 (suppl 1): i16-35. (Pubitemid 43268291)
5. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010; 16: 112-124.
6. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohn's Colitis. 2008; 2: 1-23. (Pubitemid 351179487)
7. Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009; 30: 126-137.
8. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database System Rev. 2009; 1: CD000067.
9. Thia KT, Loftus EV Jr, Sandborn WJ, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008; 103: 3167-3182.
10. Gearry RB, Barclay ML,. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005; 20: 1149-1157. (Pubitemid 41602556)
11. Kham SK, Soh CK, Liu TC, et al. Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol. 2008; 64: 373-379.
12. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170: 2-6; discussion 16-19. (Pubitemid 20015811)
13. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (suppl A): 5-36.
14. Truelove SC, Witts LJ,. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955; 2: 1041-1048.
15. Hanauer SB, Sandborn W,. Management of Crohn's disease in adults. Am J Gastroenterol. 2001; 96: 635-643. (Pubitemid 32240709)
16. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55 (suppl 1): i1-15. (Pubitemid 43268290)
17. Achkar JP, Stevens T, Easley K, et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 339-345. (Pubitemid 39029175)
18. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002; 50: 485-489. (Pubitemid 34638866)
19. Dubinsky MC,. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004; 2: 731-743. (Pubitemid 39200711)
20. Chebli JM, Gaburri PD, De Souza AF, et al. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J Gastroenterol Hepatol. 2007; 22: 268-274. (Pubitemid 46181359)
21. Mantzaris GJ, Roussos A, Kalantzis C, et al. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission? Inflamm Bowel Dis. 2007; 13: 446-450. (Pubitemid 46668250)
22. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther. 2007; 26: 217-225. (Pubitemid 46985496)
23. Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003; 38: 740-746. (Pubitemid 37161337)
24. Sood A, Midha V, Sood N, et al. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol. 2006; 12: 7332-7336. (Pubitemid 44911842)
25. Kim DU, Kim YH, Kim BJ, et al. The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease. Hepatogastroenterology. 2009; 56: 1395-1402.
26. Zheng JJ, Chu XQ, Shi XH, et al. Efficacy and safety of azathioprine maintenance therapy in a group of Crohn's disease patients in China. J Dig Dis. 2008; 9: 84-88. (Pubitemid 351566629)
27. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997; 62: 60-73. (Pubitemid 27327100)
28. Cao Q, Zhu Q, Shang Y, et al. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion. 2009; 79: 58-63.
29. Kumagai K, Hiyama K, Ishioka S, et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics. 2001; 11: 275-278. (Pubitemid 32319878)
30. Leung M, Piatkov I, Rochester C, et al. Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression. Intern Med J. 2009; 39: 121-126.
31. Krynetski EY, Evans WE,. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology. 2000; 61: 136-146.
32. Takatsu N, Matsui T, Murakami Y, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2009; 24: 1258-1264.
33. Uchiyama K, Nakamura M, Kubota T, et al. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. J Gastroenterol. 2009; 44: 197-203.
34. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134: 929-936. (Pubitemid 351451967)